Skip to Content

'
Gabriel Lopez-Berestein, M.D.

Present Title & Affiliation

Primary Appointment

Professor of Medicine, Cancer Biology, and Experimental Therapeutics, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
John Q. Gaines Foundation Professorship for Cancer Research, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor of Biomedical Sciences, Department of Integrative Biology & Pharmacology, The University of Texas Health Science Center at Houston, Houston, TX
Professor of Pharmacology, Department of Pharmacology, The University of Texas Medical School at Houston, Houston, TX
Adjunct Professor, Department of Bioengineering, Rice University, Houston, TX
Professor of NanoMedicine and Biomedical Engineering, UTHealth, Houston, TX
Adjunct Professor of Surgery, University of Puerto Rico School of Medicine, San Juan, PR

Education & Training

Degree-Granting Education

1976 Universidad de Navarra, Pamplona, Spain, MD, Immunology
1970 Universidad de Puerto Rico, Rio Piedras, PR, BS, Pre Med

Experience/Service

Academic Appointments

Faculty, University of Texas Graduate School of Biomedical Sciences, Houston, TX, 2004-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Guoyan Liu, Da Yang, Rajesha Rupaimoole, Chad V Pecot, Yan Sun, Lingegowda S. Mangala, Xia Li,. Augmentation of response to chemotherapy by microRNA-506 through regulation ,of RAD51 in serous ovarian. JNCI. In Press.
2. Zhou HY, Chen SR, Byun HS, Chen H, Li Li, Han HD, Lopez-Berestein G, Sood AK, Pan HL. Calpain-mediated KCC2 proteolytic cleavage causes disruption of chloride homeostasis in the spinal cord nad persistent neuropathic pain. Nature Communications. In Press. PMCID: PMCN/A.
3. Burcu Aslan, Paloma Monroig, Ming-Chuan Hsu, Guillermo Armaiz Pena, Cristian Rodriguez-Aguayo,. The ZNF304-integrin axis protects against anoikis in cancer. Nature. In Press.
4. Pradeep S, Huang J, Mora EM, Nick AM, Cho MS, Wu SY, Noh K, Pecot CV, Rupaimoole R, Stein MA, Brock S, Wen Y, Xiong C, Gharpure K, Hansen JM, Nagaraja AS, Previs RA, Vivas-Mejia P, Han HD, Hu W, Mangala LS, Zand B, Stagg LJ, Ladbury JE, Ozpolat B, Alpay SN, Nishimura M, Stone RL, Matsuo K, Armaiz-Peña GN, Dalton HJ, Danes C, Goodman B, Rodriguez-Aguayo C, Kruger C, Schneider A, Haghpeykar S, Jaladurgam P, Hung MC, Coleman RL, Liu J, Li C, Urbauer D, Lopez-Berestein G, Jackson DB, Sood AK. Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. e-Pub 10/14/2015. PMID: 26481148.
5. Zhang S, Lu Z, Mao W, Ahmed AA, Yang H, Zhou J, Jennings N, Rodriguez-Aguayo C, Lopez-Berestein G, Miranda R, Qiao W, Baladandayuthapani V, Li Z, Sood AK, Liu J, Le XF, Bast RC. CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis. PLoS One 10(7):e0131833, 2015. e-Pub 7/6/2015. PMCID: PMC4492679.
6. Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep 7(2):488-500, 4/24/2014. e-Pub 4/3/2014. PMCID: PMC4038960.
7. Stone RL, Baggerly KA, Armaiz-Pena GN, Kang Y, Sanguino AM, Thanapprapasr D, Dalton HJ, Bottsford-Miller J, Zand B, Akbani R, Diao L, Nick AM, Degeest K, Lopez-Berestein G, Coleman RL, Lutgendorf S, Sood AK. Focal adhesion kinase: An alternative focus for anti-angiogenesis therapy in ovarian cancer. Cancer Biol Ther 15(7). e-Pub 4/22/2014. PMCID: PMC4100993.
8. Gharpure KM, Chu KS, Bowerman C, Miyake T, Pradeep S, Mangala LS, Han HD, Rupaimoole R, Armaiz-Pena GN, Rahhal TB, Wu SY, Luft C, Napier ME, Lopez-Berestein G, Desimone JM, Sood AK. Metronomic docetaxel in PRINT(R) nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. Mol Cancer Ther. e-Pub 4/22/2014. PMCID: PMC4090269.
9. Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, Han HD, Rodriguez-Aguayo C, Bottsford-Miller J, Huang J, Miyake T, Choi HJ, Dalton HJ, Ivan C, Baggerly K, Lopez-Berestein G, Sood AK, Afshar-Kharghan V. Autocrine effects of tumor-derived complement. Cell Rep 6(6):1085-95, 3/2014. e-Pub 3/2014. PMCID: PMC4084868.
10. Ozpolat B, Sood AK, Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev 66C:110-116, 2/2014. e-Pub 12/30/2013. PMCID: PMCN/A.
11. Dalton HJ, Armaiz-Pena GN, Gonzalez-Villasana V, Lopez-Berestein G, Bar-Eli M, Sood AK. Monocyte Subpopulations in Angiogenesis. Cancer Res 5, 74. e-Pub 2/2014. PMCID: PMC4040005.
12. Jain P, Kantarjian H, Estey E, Pierce S, Cortes J, Lopez-Berestein G, Ravandi F. Single-Agent Liposomal All-Trans-Retinoic Acid as Initial Therapy for Acute Promyelocytic Leukemia: 13-Year Follow-Up Data. Clin Lymphoma Myeloma Leuk 14(1):e47-9, 2/2014. e-Pub 10/2013. PMCID: PMC4103408.
13. Zhaorigetu S, Rodriguez-Aguayo C, Sood AK, Lopez-Berestein G, Walton BL. Delivery of negatively charged liposomes into the atherosclerotic plaque of apolipoprotein E-deficient mouse aortic tissue. J Liposome Res. e-Pub 1/2014. PMCID: PMCN/A.
14. Bradley A, Zheng H, Ziebarth A, Sakati W, Branham-O'Connor M, Blumer JB, Liu Y, Kistner-Griffin E, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Landen CN, Eblen ST. EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer. Carcinogenesis. e-Pub 1/2014. PMCID: PMC4004201.
15. Gaur P, Sceusi EL, Samuel S, Xia L, Fan F, Zhou Y, Lu J, Tozzi F, Lopez-Berestein G, Vivas-Mejia P, Rashid A, Fleming JB, Abdalla EK, Curley SA, Vauthey JN, Sood AK, Yao JC, Ellis LM. Identification of Cancer Stem Cells in Human Gastrointestinal Carcinoid and Neuroendocrine Tumors. Gastroenterology 141(5), 11/2011. PMCID: PMC3202668.
16. Yaser R. Hussein, Anil K. Sood, Sudeshna Bandyopadhyay, Bassam Albashiti , Assaad Semaan, Zeina Nahleh, Juwon Roh, Hee Dong Han, Gabriel Lopez-Berestein , Rouba Ali-Fehmi. Clinical and Biological Relevance of EZH2 in Triple-Negative Breast Cancer Human Pathology. Human Pathology. Submitted. PMCID: PMCN/A.
17. Gonzalez-Villasana, Vianey, Lopez-Berestein, Gabriel. Rac1/Pak1/p38/MMP-2 axis regulates angiogenesis in ovarian cancer. The Journal of Clinical Investigation. Submitted. PMCID: PMCN/A.
18. Tekedereli I, Akar U, Alpay N, Lopez-Berestein G, Sood A, Ozpolat B. Therapeutic targeting of EF2K by siRNA inhibits tumor growth. Molecular Cancer Therapeutics. Submitted. PMCID: PMCN/A.
19. Tekedereli I, Akar U, Alpay N, Lopez-Berestein G, Sood A, Ozpolat B. Therapeutic targeting of Bcl-2 by systemically administred nanoliposomal siRNA inhibits tumor growth of ER(-) and ER(+) breast cancer xenografts by inducing authophagic and apoptotic cell death. Gene Therapy. Submitted. PMCID: PMCN/A.

Book Chapters

1. Rodriguez-Aguayo C, Chavez-Reyes A, Lopez-Berestein G, Sood AK. Advanced Delivery and Therapeutic Applications of RNAi. In: RNAi in Cancer Therapy. John Wiley & Sons. Inc. In Press.
2. Ozpolat B, Akar U, Dalby K, Lopez-Berestein G. Induction of Autophagic Cell Death by Polyphenolic Compounds in Cancer: A Novel Strategy to Treat Cancer. In: Cell Death Mechanisms in Cancer. Springer. In Press.
3. Tekedereli I, Lopez-Berestein G, Ozpolat B. Induction of Autophagic Cell Death by Targeting Bcl-2 as A Novel Theraputic Strategy in Breast Cancer. In: Breast Cancer. Open Access. In Press.

Last updated: 11/2/2015